ReviewMarine drugs2026
Cnidarian Venoms in the Omics Era: Toxin Discovery and Bioactive Potential.
Review in Marine drugs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Cnidaria is a phylum of aquatic invertebrates that includes jellyfish, sea anemones and corals. Their venoms are among the oldest in the animal kingdom and an important source of bioactive molecules. Advances in omics technologies have revolutionized toxin discovery, yet knowledge of cnidarian toxin diversity remains fragmented across databases and individual studies. To address this gap, this review integrates information from 342 toxins curated in the ToxProt database, 76 additional toxins reported in the literature, and evidence from 81 proteomic and 31 transcriptomic studies. Toxins have been characterized from 145 species, with sea anemones accounting for the largest number of studied species (65). Cnidarian toxins are used for prey capture, predator deterrence, territorial competition and digestion. These include toxic enzymes, neurotoxins, protease inhibitors and pore-forming toxins, among others. To date, the three-dimensional structures of 37 toxins have been resolved, and 78 have reported biomedical or biotechnological potential, including antiarrhythmic, analgesic, anticancer, and insecticidal activities. According to omics studies, metalloproteinases, phospholipases, lectins, Kunitz-like peptides, venom coagulation factor and CRiSP/CAP toxins are the most widespread, whereas neurotoxins show a more restricted taxonomic distribution. The first venom-related transcriptomic analysis of three Corallimorpharia and two Antipatharia (black corals) species demonstrates putative pore-forming toxins, while black corals also harbor putative neurotoxins. Overall, this review synthesizes the current knowledge of cnidarian venoms and highlights their remarkable diversity and promise as a source of bioactive molecules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.